Today: 6 December 2025
Subscribe
Browse Category

Biotech News News 9 November 2025 - 24 November 2025

Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio Inc. has become one of the hottest tickers in biotech this week. On November 20, 2025, NUVB is trading near a three‑year high after a powerful earnings beat, accelerating uptake of its lung‑cancer drug IBTROZI™ (taletrectinib), and a
20 November 2025
 ·  ·  ·  ·  · 
Anavex Life Sciences (AVXL) Stock Plunges After EMA Issues Negative Trend Vote on Alzheimer’s Drug

Anavex Life Sciences (AVXL) Stock Plunges After EMA Issues Negative Trend Vote on Alzheimer’s Drug

Anavex Life Sciences (NASDAQ: AVXL) tumbled on November 14, 2025 after Europe’s drug regulator delivered a negative trend vote on its Alzheimer’s candidate blarcamesine. The company plans a CHMP re-examination and a fresh meeting with the FDA. Here’s what happened
14 November 2025
 ·  ·  ·  ·  · 
Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (NASDAQ: MRSN) is back in the headlines in a big way today after announcing a definitive agreement to be acquired by Day One Biopharmaceuticals in a deal worth up to approximately $285 million. The news has sent MRSN
13 November 2025
 ·  ·  ·  · 
Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals (SLRX) Stock Jumps as $7M Offering Prices; Closing Expected November 12, 2025 Amid Decoy Therapeutics Merger

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is back in the headlines today after pricing a $7 million underwritten public offering tied to its pending business combination with Decoy Therapeutics. The company said the deal is expected to close “on or about
12 November 2025
 ·  ·  ·  · 
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) extended this week’s rally on Wednesday as investors digested fresh late‑stage results for its investigational oral PCSK9 inhibitor and an FDA clearance that supports broader precision use of Keytruda-based therapy. Below is what changed
12 November 2025
 ·  ·  ·  ·  · 
Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

Aspire Biopharma (ASBP) Whipsaws on Heavy Volume Today as Investors Eye Reverse‑Split Authority and Nasdaq Compliance — Nov. 11, 2025

What moved ASBP today (Nov. 11) Trading in Aspire Biopharma swung sharply. A pre‑market “health‑care movers” screen showed ASBP briefly up more than 30%, before regular‑session selling pulled shares lower on very heavy volume. Mid‑session, ASBP was down roughly 20–25%
11 November 2025
 ·  ·  ·  ·  · 
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly and Company (NYSE: LLY) opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and
10 November 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto (GLTO) Soars on Damora Therapeutics Acquisition and $285M Financing: IND in 2026, Proof‑of‑Concept in 2027

Galecto, Inc. (NASDAQ: GLTO) said this morning it completed the acquisition of Damora Therapeutics and closed a $284.9 million oversubscribed private placement, a one‑two punch that instantly refocuses the company on mutant calreticulin (mutCALR) therapies for myeloproliferative neoplasms (MPNs) and
10 November 2025
 ·  ·  ·  ·  · 
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Market snapshot Last close (Fri, Nov 7): $36.77.Intraday range: $34.69 – $37.50; volume: ~4.65M. Why VKTX is back on watch this week 1) Fresh institutional interest and ownership trends Ethos Financial Group’s new position adds to a year when institutions
9 November 2025
 ·  ·  ·  ·  · 
1 2 3 4
Go toTop